Tenet Healthcare Corporation (THC)
Is Tenet (THC) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Tenet Healthcare Corporation (THC) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Tenet (THC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Tenet Stock Jumps 19.6% Since Q3 Results: What Should Investors Do?
THC continues to experience strong demand for its services, which is expected to continue throughout the year.
Bull of the Day: Tenet Healthcare (THC)
Tenet Healthcare shares have been scorching-hot in 2024, up 115% and outperforming many of the Mag 7 members.
Tenet (THC) Is Attractively Priced Despite Fast-paced Momentum
Tenet (THC) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Tenet Healthcare: Targeting More Stable Demand In High-Acuity Services
Tenet Healthcare is currently shifting towards a more stable demand for high-acuity service. The company is committed to continued expansion and allocated yearly budget to improve its Ambulatory Care Services. Posted an improving margin and has positive outlook from the management.
Here's Why Tenet Healthcare (THC) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Tenet Healthcare Corporation (THC) Q3 2024 Earnings Call Transcript
Tenet Healthcare Corporation (NYSE:THC ) Q3 2024 Earnings Conference Call October 29, 2024 10:00 AM ET Company Participants Will McDowell – Vice President-Investor Relations Saum Sutaria – Chairman and Chief Executive Officer Sun Park – Executive Vice President and Chief Financial Officer Conference Call Participants Josh Raskin – Nephron Research Ben Hendrix – RBC Capital Markets A.J. Rice – UBS Stephen Baxter – Wells Fargo Ann Hynes – Mizuho Michael Ha – Baird Pito Chickering – Deutsche Bank Justin Lake – Wolfe Research Joanna Gajuk – Bank of America Whit Mayo – Leerink Partners Andrew Mok – Barclays Brian Tanquilut – Jefferies Matthew Gillmor – KeyBanc Capital Markets Sarah James – Cantor Fitzgerald John Ransom – Raymond James Jamie Perse – Goldman Sachs Operator Good morning, and welcome to Tenet Healthcare's Third Quarter 2024 Earnings Conference Call.
Tenet (THC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Tenet (THC) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Tenet Healthcare (THC) Beats Q3 Earnings and Revenue Estimates
Tenet Healthcare (THC) came out with quarterly earnings of $2.93 per share, beating the Zacks Consensus Estimate of $2.33 per share. This compares to earnings of $1.44 per share a year ago.
Stay Ahead of the Game With Tenet (THC) Q3 Earnings: Wall Street's Insights on Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Tenet (THC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
A Dose of Growth? Why Tenet Healthcare Could be a Buy Pre-Q3 Earnings
THC's third-quarter results are likely to reflect growing patient admissions, utilization and patient days.
